Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of -4.89% and Operating profit at -227.52% over the last 5 years
2
The company has declared Negative results for the last 9 consecutive quarters
3
Risky -
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,605 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.21
-24.80%
0.93
Revenue and Profits:
Net Sales:
178 Million
(Quarterly Results - Jun 2025)
Net Profit:
-93 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.45%
0%
2.45%
6 Months
0.51%
0%
0.51%
1 Year
-14.45%
0%
-14.45%
2 Years
-41.34%
0%
-41.34%
3 Years
-70.63%
0%
-70.63%
4 Years
-79.72%
0%
-79.72%
5 Years
-84.18%
0%
-84.18%
Guangdong Hybribio Biotech Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.89%
EBIT Growth (5y)
-227.52%
EBIT to Interest (avg)
47.61
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
0.33
Tax Ratio
14.53%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
27.34%
ROE (avg)
16.32%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.93
EV to EBIT
-3.30
EV to EBITDA
-4.34
EV to Capital Employed
0.91
EV to Sales
3.94
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-27.44%
ROE (Latest)
-24.80%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
178.50
132.30
34.92%
Operating Profit (PBDIT) excl Other Income
-61.60
1.00
-6,260.00%
Interest
0.50
0.50
Exceptional Items
4.40
-0.00
Consolidate Net Profit
-92.80
-44.40
-109.01%
Operating Profit Margin (Excl OI)
-597.50%
-333.00%
-26.45%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 34.92% vs -34.41% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -109.01% vs 91.92% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
804.30
1,094.10
-26.49%
Operating Profit (PBDIT) excl Other Income
-615.10
189.10
-425.28%
Interest
2.30
6.10
-62.30%
Exceptional Items
-18.60
-1.50
-1,140.00%
Consolidate Net Profit
-950.40
68.50
-1,487.45%
Operating Profit Margin (Excl OI)
-1,011.40%
-2.90%
-100.85%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -26.49% vs -80.38% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -1,487.45% vs -96.20% in Dec 2023
About Guangdong Hybribio Biotech Co., Ltd. 
Guangdong Hybribio Biotech Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






